Stellate Therapeutics Publishes Positive Results in PLOS ONE on Neuroprotective Properties of Lead Candidate STL-101
September 01, 2021 02:00 ET
|
Stellate Therapeutics
Stellate Therapeutics Publishes Positive Results in PLOS ONE on Neuroprotective Properties of Lead Candidate STL-101 Paris, France – 1 September 2021: Stellate Therapeutics Inc. (“the Company”,...
Stellate Therapeutics Strengthens Senior Management Team
June 17, 2021 01:00 ET
|
Stellate Therapeutics
Stellate Therapeutics Strengthens Senior Management Team David Immke joins as Chief Scientific Officer and Jonathan Weiss as Director of Business Development Paris, France – 17 June 2021: Stellate...